Episode 24: Aducanumab and Alzheimer Disease Clinical Trials

This episode is part of a NeurologyLive series on aducanumab's journey to the FDA and the challenges of conducting clinical trials in Alzheimer disease. For part 1, click here. For part 2, click here.

Episode 24 of the NeurologyLive Mind Moments podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.

The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

Episode 24, "Aducanumab and Alzheimer Disease Clinical Trials," features interviews with Lon Schneider, MD, MS, Della Martin Chair in Psychiatry and Neuroscience, University of Southern California Keck School of Medicine; Marwan Sabbagh, MD, director, Lou Ruvo Center for Brain Health, Cleveland Clinic; Stephen Salloway, MD, MS, director, Neurology and the Memory and Aging Program, Butler Hospital; Richard S. Isaacson, MD, director, Alzheimer’s Prevention Clinic, Weill Cornell Medicine; and Anton Porsteinsson, MD, director, Alzheimer's Disease Care, Research, and Education Program, University of Rochester.

Each of these experts provided their perspective and insight into what’s been happening in the conversations around aducanumab and why there is some controversy around its clinical trial data, as well as how all of this speaks to the intricacies and difficulties in actually conducting clinical trials in Alzheimer disease.

Click here to subscribe to the Mind Moments podcast. Be sure to leave a rating and review for the show. Thanks for listening!